Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery

TAIPEI, Jan. 26, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a licensing agreement with CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA ("Cristália"), for exclusive Brazilian rights to the commercialization of APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for the treatment of inflammation and pain following ocular surgery.  APP13007 is currently under review by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) date of March 4, 2024.  The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.

APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNTtm nanoparticle formulation platform.  The novel formulation enables a convenient and straightforward dosing regimen (twice daily for 14 days) while providing rapid and sustained relief of inflammation and pain, which in Phase 3 trials proved statistically and clinically superior to its matching placebo (p<0.001).  If approved, APP13007 will join in a potential and growing market in Brazil for topical ophthalmic steroids.

"We are honored to establish this partnership with Cristália, with its storied history in Brazilian pharmaceuticals and expertise in eye health.  Given their dedication to bringing innovation to the market, we are confident APP13007 will reach its potential in providing ophthalmologists and patients a powerful option in recovering from ocular surgery," said Erick Co, President and CEO of Formosa Pharmaceuticals.

Ricardo S. Pacheco, Chairman of Cristália stated: "We are pleased to have entered into this agreement with our development partner, Formosa Pharmaceuticals. If approved, APP13007 will be an attractive new treatment option to ophthalmic surgeons and their patients in Latin America with a convenient posology. Once is approved, Cristália will go full steam ahead with commercialization."

About Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology.  The company's proprietary nanoparticle formulation technology (APNTtm), through which APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration.  Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in delivery and penetration to target tissues.  For more details about Formosa Pharma and APNTtm, visit www.formosapharma.com.

About Cristália

Established 51 years ago, Cristália Laboratory is a 100% Brazilian Pharmaceutical, Pharmochemical, Biotechnological, Research/Development/Innovation-based Industrial Complex. It is a pioneer in thoroughly executing a drug production chain, from its molecule design to the finished product. The company holds 127 patents ? a national record ? and is a market leader in anesthesia in Latin America. Occupying a forefront position when it comes to innovation, Cristália produces 53% of the raw materials of its drugs at its Pharmacochemical plant. The company is present in over 95% of Brazilian hospitals, being an international reference in active substances and finished products exportation to over 30 countries. For the last 20 years, the company has been investing in biotechnology, owning some of Brazil's first private Biotech plants. Cristália Group has about 5,000 colleagues. | www.cristalia.com.br.

SOURCE Formosa Pharmaceuticals Inc.